Navigation Links
Do you want to know another role of ribonucleotide reductase M2?

Colorectal cancer (CRC) is the leading cause of cancer-related death worldwide. In addition, the incidence and mortality rates of colorectal cancer are on the rise. Recently, metabolic genes have received increasing and specific attention due to their potential role in carcinogenesis.

Previous studies have shown that alterations in ribonucleotide reductase (RR) levels may significantly influence the biological properties of cells, including tumor promotion and tumor progression, suggesting that RR may be implicated in tumorigenesis. Recent findings have established that p53R2 suppresses the invasiveness of cancer cells, and its expression is associated with a better survival prognosis for CRC patients; however, the function of RRM2 in CRC is unclear. Here, we demonstrate that RRM2 may play an important role in the development of CRC and may contribute to the response to UV irradiation.

A research article to be published on September 14, 2012 in the World Journal of Gastroenterology addresses this question. The research team led by Prof. Lu from Shanghai Minimally Invasive Surgery Center (Ruijin Hospital, Shanghai Jiaotong University School of Medicine) from China investigated the roles of the hRRM2 subunit in colorectal cancer and UV-induced DNA damage repair.

The results showed that RRM2 overexpression was positively correlated with invasion depth, poorly differentiated type, and tumor, node, metastasis stage. The expression of RRM2 in HCT116 cells was down-regulated after transfection, and HCT116 cell proliferation was obviously suppressed. In the invasion test, the number of cells that passed through the chambers in the RRM2-siRNA group was lower than that in the negative control groups. The results suggest that RRM2 overexpression may be associated with colorectal cancer progression. RRM2 silencing by siRNA may inhibit the hyperplasia and invasiveness of colorectal cancer cells, suggesting that RRM2 may play an important role in the infiltration and metastasis of colorectal cancer, which is a potential therapeutic strategy in colorectal cancer. In addition, RRM2 depletion increased UV sensitivity.

The researchers drew a conclusion that RRM2 may be a facilitating factor in colorectal tumorigenesis and UV-induced DNA damage repair.

Their study suggests that RRM2 silencing may inhibit the hyperplasia and invasiveness of colorectal cancer cells. RRM2 may play an important role in the infiltration and metastasis of colorectal cancer and that suppression of its function could be a potential therapeutic strategy in colorectal cancer.


Contact: Ling-Ling Wen
World Journal of Gastroenterology

Related medicine news :

1. Many US schools are unprepared for another pandemic
2. Yet Another Tick-Borne Illness Emerges in U.S.
3. Enzymes implicated in disease processes attack one another instead of harming body proteins
4. NCH CIRP awarded CDC Injury Control Research Center designation, another 5 years
5. Daily Aspirin May Cut Cancer Deaths, Another Study Finds
6. CDC Warns of Another Emerging Tick-Borne Threat
7. Google Rolls Out Another Panda Algorithm Update – Small Businesses Plan for the Future of SEO
8. Another Drug Take-Back Day Scheduled for Saturday
Post Your Comments:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: